These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27374678)

  • 1. Non-occlusive Mesenteric Ischemia with Diabetic Ketoacidosis and Lactic Acidosis Following the Administration of a Sodium Glucose Co-transporter 2 Inhibitor.
    Gocho N; Aoki E; Okada C; Omura K; Hirashima T; Suzuki N; Tanaka H; Omori Y
    Intern Med; 2016; 55(13):1755-60. PubMed ID: 27374678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diabetic ketoacidosis with mild hyperglycemia associated with the use of canagliflozin. Report of one case with type 1 diabetes].
    Novik A V; García B C; Oliva I D
    Rev Med Chil; 2017 Mar; 145(3):393-396. PubMed ID: 28548198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis.
    Bloomgarden ZT
    J Diabetes; 2016 Mar; 8(2):175-6. PubMed ID: 26611882
    [No Abstract]   [Full Text] [Related]  

  • 4. Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
    Adachi J; Inaba Y; Maki C
    Intern Med; 2017; 56(2):187-190. PubMed ID: 28090050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-glucose cotransporter 2 inhibitor-associated diabetic ketoacidosis: Report of two cases with hyperglycemic ketoacidosis in type 1 diabetes.
    Harati H; Sharma V; Motazedi A
    J Diabetes; 2016 Jan; 8(1):165. PubMed ID: 26211700
    [No Abstract]   [Full Text] [Related]  

  • 6. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT.
    Tahir H; Wani A; Daruwalla V; Daboul N; Sagi J
    J Ayub Med Coll Abbottabad; 2015; 27(4):923-4. PubMed ID: 27004352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes.
    Shamchuk A; Doulla M; Jetha M
    CMAJ; 2021 Sep; 193(35):E1385-E1388. PubMed ID: 34493565
    [No Abstract]   [Full Text] [Related]  

  • 9. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
    Andrews TJ; Cox RD; Parker C; Kolb J
    J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fournier's Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: Life-Threatening Complications.
    Kasbawala K; Stamatiades GA; Majumdar SK
    Am J Case Rep; 2020 Jun; 21():e921536. PubMed ID: 32483108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactic acidosis associated with Glucophage use in a man with normal renal and hepatic function.
    Pepper GM; Schwartz M
    Diabetes Care; 1997 Feb; 20(2):232-3. PubMed ID: 9118782
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium-glucose Cotransporter 2 Inhibitor-induced Diabetic Ketoacidosis in a Type 2 Diabetic Patient.
    Ramirez Tello EM; Orellana-Barrios MA; Nugent K
    Am J Med Sci; 2016 Jun; 351(6):634-5. PubMed ID: 27238930
    [No Abstract]   [Full Text] [Related]  

  • 14. Diabetic ketoacidosis associated to canagliflozin in type 2 diabetes.
    González Sanchidrián S; Gómez-Martino Arroyo JR; Labrador Gómez PJ
    Med Clin (Barc); 2017 Feb; 148(4):e19-e20. PubMed ID: 28041622
    [No Abstract]   [Full Text] [Related]  

  • 15. [Severe diabetic ketoacidosis, acute kidney injury and dehydration due to canagliflozin in type 2 diabetes mellitus patient: Atypical clinical presentation].
    Moreno Obregón F; Espino Montoro A; Marín Martín J; León Jiménez D
    Aten Primaria; 2019 Dec; 51(10):664-666. PubMed ID: 31326123
    [No Abstract]   [Full Text] [Related]  

  • 16. Euglycemic diabetic ketoacidosis with canagliflozin: Not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use.
    Clement M; Senior P
    Can Fam Physician; 2016 Sep; 62(9):725-8. PubMed ID: 27629668
    [No Abstract]   [Full Text] [Related]  

  • 17. Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.
    Jazi M; Porfiris G
    Can Fam Physician; 2016 Sep; 62(9):722-4. PubMed ID: 27629667
    [No Abstract]   [Full Text] [Related]  

  • 18. ‘Euglycemic’ Ketoacidosis in a Patient With Type 2 Diabetes Being Treated With Canagliflozin.
    Danford C; Chan P; Magill SB
    WMJ; 2016 Aug; 115(4):206-9. PubMed ID: 29099159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SGLT2 Inhibitors and Euglycemic Ketoacidosis.
    Masuta P; Johri G; Paul M
    Am J Ther; 2018; 25(4):e498-e500. PubMed ID: 28537992
    [No Abstract]   [Full Text] [Related]  

  • 20. Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
    Rashid O; Farooq S; Kiran Z; Islam N
    BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27177938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.